The company
Beam Therapeutics Inc.
BEAM · Nasdaq
BEAM stood above a rising 150-day average in 34 of the last 52 weekly readings, and has been out of that trend for the last 14 weeks. It is 14.4% below that average now. Genomics & Gene Editing: 20% of its 5 stocks in an uptrend (−40 points in four weeks); Health Care: 26% (−10 points in four weeks).
Statistics
- Rotation
- Not moving yet
- Weeks in an uptrend
- out for 14
- Industry in uptrend
- 20% -40 in 4 wk
- Insider buys, 12 months
- $0
- Insider sales, 12 months
- $38.3M
- Officials’ trades on record
- 0
- Institutions holding
- 263 (+26)
In the rotation
Each square a week: lit when it closed above a rising 150-day average. 34 of 52 weeks.
Genomics & Gene Editing: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.
Money in and out
Open-market buys above the line and sales below, in dollars.
Congress and officials
No member of Congress or official has disclosed a trade in it.
Insiders
| Who | Did | Shares | Traded |
|---|---|---|---|
| John M. EvansCEO | sold | 25,000at $23.98 | 16 Oct 2026filed 16 Oct 2026 |
| John M. EvansCEO | sold | 25,000at $23.57 | 15 Oct 2026filed 16 Oct 2026 |
| Bethany J. CavanaghSVP, Finance and Treasurer | sold | 187at $24.41 | 1 Oct 2026filed 2 Oct 2026 |
| Amy SimonChief Medical Officer | sold | 16,667at $25.74 | 27 Jul 2026filed 29 Jul 2026 |
| John M. EvansCEO | sold | 23,100at $34.26 | 30 Jun 2026filed 1 Jul 2026 |
| John M. EvansCEO | sold | 1,900at $34.84 | 30 Jun 2026filed 1 Jul 2026 |
| Amy SimonChief Medical Officer | sold | 373at $34.73 | 30 Jun 2026filed 2 Jul 2026 |
| John M. EvansCEO | sold | 13,421at $35.13 | 29 Jun 2026filed 1 Jul 2026 |
| John M. EvansCEO | sold | 11,579at $35.91 | 29 Jun 2026filed 1 Jul 2026 |
| Fmr Llc10% owner, Other | sold | 251,488at $35.26 | 26 Jun 2026filed 29 Jun 2026 |
| Fmr Llc10% owner, Other | sold | 33,372at $35.12 | 25 Jun 2026filed 29 Jun 2026 |
| Giuseppe CiaramellaPresident | sold | 11,810at $24.58 | 1 Apr 2026filed 6 Apr 2026 |
Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.
Institutions
Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.
| Manager | Shares | Change |
|---|---|---|
| FMR LLCadded · filed 13 Aug 2026 | 12,609,002$432.7M | +156,803+1.3% |
| FARALLON CAPITAL MANAGEMENT, L.L.C.added · filed 14 Aug 2026 | 10,236,396$351.3M | +101,700+1.0% |
| ARK Investment Management LLCreduced · filed 14 Aug 2026 | 10,234,862$351.3M | -1,898,571−15.6% |
| BlackRock, Inc.added · filed 7 Aug 2026 | 8,997,542$308.8M | +509,973+6.0% |
| STATE STREET CORPadded · filed 7 Aug 2026 | 5,827,122$200.0M | +127,857+2.2% |
| VANGUARD PORTFOLIO MANAGEMENT LLCadded · filed 13 Aug 2026 | 4,921,259$168.9M | +350,462+7.7% |
| VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 2026 | 4,599,437$157.9M | +222,063+5.1% |
| ARCH Venture Management, LLCunchanged · filed 14 Aug 2026 | 4,540,132$155.8M | 00.0% |
| Sumitomo Mitsui Trust Group, Inc.reduced · filed 30 Jul 2026 | 3,455,043$118.6M | -370,542−9.7% |
| Amova Asset Management Americas, Inc.reduced · filed 13 Aug 2026 | 3,455,043$118.5M | -370,542−9.7% |
News
Everyone who traded it
Same industry
Government contracts
No federal award is tied to it.
From its SEC filings
Analyst forecasts
No analyst forecasts yet.